Revascularization could improve areas traditionally considered necrotic

Original title: Prevalence of Regional Myocardial Thinning and Relationship With Myocardial Scarring in Patients With Coronary Artery Disease. Reference: Dipan J. Shah et al. JAMA. 2013;309(9):909-918

Regional left ventricular (LV) wall thinning is believed to represent chronic myocardial infarction. In fact, the most recent guidelines, both European and American, have concluded that “Images that show regional myocardial thinning in absence of contraction with no other cause than the ischemic, are diagnosed as chronic infarction”. Regional left ventricular (LV) wall thinning is believed to represent chronic myocardial infarction. However, recent case reports using delayed-enhancement cardiovascular magnetic resonance (CMR) imaging raise the possibility that thinning may occur with little or no scarring. 

The recent incorporation of Delayed Enhancement MR imaging to the study of patients with ischemic heart disease could change the previous paradigm. This prospective study included 1055 patients with a history of ischemic heart disease between 2000 and 2008, where diagnosed through 1.5T DE-MR in 1.5T. A ≤ 5.5 mm thinning was considered at the end of diastole. Scarring tissue was also analyzed (hyperintense areas) within thinning. Of 1055 patients analyzed, 201 (19%) had regional wall thinning of some LV area.

Among patients with thinning undergoing revascularization and follow-up CMR (RR=0.72, p<0.001), there was improvement in the systolic global function (RR=0.53, p<0.001) and a reduction in end-diastole volume (RR=0.42, p=0.007). It was also observed that the Q waves disappeared from the ECG. The latter was inversely correlated to scar extent within the thinned region.

Conclusion: 

Among patients with CAD referred for CMR and found to have regional wall thinning, limited scar burden was present in 18% and was associated with improved contractility and resolution of wall thinning after revascularization.

Editorial Comment: 

This study has a major limitation, the decision to revascularize was left to the attending physicians, which could affect selection. These results contradict the present guidelines and paradigmes and require further randomized studies for confirmation. 

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...